David S Rosenthal > Dechert LLP > New York, United States > Lawyer Profile

Dechert LLP
Three Bryant Park, 1095 Avenue of the Americas
NEW YORK, NY 10036-6797
United States

Lawyer Rankings

United States > Finance > Capital markets: debt

Acting primarily for issuers, Dechert LLP is noted as ‘a leader in advising business development companies’, and is also well known in the life sciences sector. Recent highlights included James Lebovitz, who splits his time between Philadelphia and New York, advising a business development company on a $500m senior notes offering. In a high-profile multi-jurisdictional deal, Philadelphia partners William Lawlor and Ian Hartman advised Crown Holdings on two private placements of notes worth €335m and €500m respectively, which were issued by its French subsidiary. The team also advised Crown on a $875m private placement of notes issued by US subsidiaries. Boston-based Thomas Friedmann and New-York based David Rosenthal co-chair the corporate finance and capital markets practice.

United States > Finance > Capital markets: equity offerings

Collaborative, involved, professional and prompt’, Dechert LLP attracts praise for ‘seeking to understand the client’s business to provide a value-add service. The group, which acts for corporate issuers and investment banks, is particularly prominent in advising business development companies and life sciences clients on equity deals. Among its recent highlights, Philadelphia-based private equity specialist Kenneth Young advised Corporate Capital Trust, a business development company, on its NYSE listing. New York-based group co-chair David Rosenthal (‘a trusted and valued advisor’) acted alongside Philadelphia’s Gregory Schernecke to advise Aquestive Therapeutics on its $67.5m IPO. Other key contacts include Boston-based department co-chair Thomas Friedmann, Philadelphia-based James Lebovitz and business development company specialist Harry Pangas, who recently joined in Washington DC from Eversheds Sutherland.

United States > Finance > Capital markets: global offerings

Business-oriented, committed and knowledgeable’, according to one source, Dechert LLP’s capital markets practice ‘works closely with the client to provide an active and prominent voice in internal dialogues’. The group, which is well weighted between issuer and manager mandates, attracts particular praise as ‘a specialist advisor to business development companies’; it is also well versed in life sciences matters. In a significant cross-border highlight, Philadelphia-based partners William Lawlor and Ian Hartman advised Crown Holdings on two euro-denominated private placements of notes worth a combined €835m (issued by a French subsidiary of Crown) and a simultaneous $875m private placement of notes (issued by US subsidiaries of Crown) — the team was supported by lawyers in London, Paris and Luxembourg. Boston-based Thomas Friedmann, who advised PennantPark Floating Rate Capital on its $138.6m notes offering in Israel, and New York-based David Rosenthal, who ‘seeks to understand the client’s business’, jointly lead the department.

United States > Finance > Capital markets: high-yield debt offerings

Dechert LLP’s high-yield debt practice is mainly active on behalf of issuers, with its client roster dominated by life sciences companies and permanent capital vehicles. The practice group, commended by sources for its ‘collaborative and business-focused approach’, can also draw on its global network for support in multi-jurisdictional matters. In Philadelphia, Stephen Leitzell recently advised B&G Foods on a $400m senior notes offering. New York-based life sciences expert David Rosenthal and Boston-based Thomas Friedmann co-chair the department.

United States > Industry focus > Healthcare: life sciences

The ‘highly creative’ practice at Dechert LLP is co-headed by Andrea L C Reid in Boston and David S Rosenthal in New York, who focus on IP and corporate work respectively. Reid advised clinical-stage biopharmaceutical company PureTech Health on IP-related aspects of its deal with Hoffman-La Roche to advance its milk-derived exosome platform technology for the oral administration of Roche’s antisense oligonucleotide platform. Rosenthal has assisted Egalet with an asset purchase agreement to acquire four FDA-approved, non-narcotic pain products from Iroko. Product liability litigators Sheila Birnbaum and Mark Cheffo, who joined the New York office from Quinn Emanuel Urquhart & Sullivan, LLP in July 2018, have been acting for Purdue in over 1,400 cases related to its prescription opioid pain medications. Patent specialist Chad Davis from Goodwin is another recent arrival in Boston. The ‘incredibleCarl Morales in New York, who is experienced in developing and prosecuting patent portfolios for FDA-approved or soon-to-be approved drug products, is also recommended.